ARWR - Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

• Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) said filed an application to get clearance to start a phase 1/2a trial of ARO-MMP7 to treat idiopathic pulmonary fibrosis (IPF).
• The company added that it filed application to a local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials.
• Pending clearance, Arrowhead intends to start the study, dubbed AROMMP7-1001, in up to 56 healthy volunteers and in up to 21 patients with IPF.
• IPF is a condition in which the lungs become scarred and breathing becomes increasingly difficult.

For further details see: